CD80 and cancer: The results showed that the majority of the circulating PD-1+ and CD80+ sEVs in both healthy donors and cancer patients were positive for CD45, suggesting that immunocytes were the main source of PD-1/CD80+ sEVs regardless of tumour development (Supplementary Fig. 2a).